Biocon Biologics commercial partner launches psoriatic arthritis injection in Japan

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).

In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan upon regulatory approval.

Read also: Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis

Biocon Biologics’ biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in December 2024.

Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions.

Read also: Biocon Biologics secures multiple market access agreements in US for Yesintek

Biocon Biologics is a global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas.

Read also: Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics